PF-08046054 by Pfizer for Ovarian Cancer: Likelihood of Approval

PF-08046054 is under clinical development by Pfizer and currently in Phase I for Ovarian Cancer.

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher

October 30, 2023

Cybin Adds To Its Industry-Leading Psychedelic Patent Portfolio

Cybin Inc. (NEO: CYBN) (NYSEAMERICAN: CYBN) has added another significant patent acquisition today in its portfolio today. The company announced the issuance of U.S. Patent 11,724,985

August 15, 2023

AbbVie steps up to the plate with MLB player for IBD awareness

When Dexter Fowler was diagnosed with ulcerative colitis at age 22, he bought a book called Crohn’s and Colitis for Dummies. There were few online

June 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.